%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
117 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-08-06T14:59:49Z
2024-03-28T07:13:30-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T07:13:30-07:00
application/pdf
Heather
2001-1004.sept
uuid:30601752-1dd2-11b2-0a00-eb08271d5700
uuid:30601754-1dd2-11b2-0a00-bf0000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
19 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
147 0 obj
[151 0 R]
endobj
148 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 46 732.5293 Tm
[(14.)-875.1 (Koopmanschap MA, Rutten FF)79.7 (. )17.7 (The impact of indirect costs on)]TJ
2.175 -1.25 Td
(outcomes of health care programs. Health Econ 1994;3:385-93.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Koopmanschap MA, Rutten FF)79.7 (. Indirect costs: the consequence of)]TJ
2.175 -1.25 Td
(production loss or increased costs of production. Med Care)Tj
0 Tc 0 Tw 0 -1.25 TD
(1996;34:DS59-68.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Koopmanschap MA, Rutten FF)79.7 (. )54.8 (A)-220.1 (practical guide for calculating)]TJ
2.175 -1.25 Td
(indirect costs of disease. Pharmacoeconomics 1996;10:460-6.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Thompson SG, Barber JA. How should cost data in pragmatic trials)]TJ
2.175 -1.25 Td
[(be analysed? BMJ 2000;320:1)36.8 (197-2000.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Efron B, )17.7 (T)35 (ibshirani RJ. )54.8 (An introduction to the bootstrap. New )36.8 (Y)99.8 (ork,)]TJ
2.175 -1.25 Td
(London: Chapman & Hall; 1993.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Briggs )54.8 (A, Fenn P)110.7 (. Confidence intervals or surfaces? Uncertainty on)]TJ
2.175 -1.25 Td
[(the cost-ef)17.7 (fectiveness plane. Health Econ 1998;7:723-40.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Johannesson M. Second opinion: On the estimation of )]TJ
2.175 -1.25 Td
[(cost-ef)17.7 (fectiveness ratios. Health Policy 1995;31:225-9.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Chaudhary MA, Stearns SC. Estimating confidence intervals for)]TJ
2.175 -1.25 Td
[(cost-ef)17.7 (fectiveness ratios: an example from a randomised trial. Stat)]TJ
0 Tc T*
(Med 1996;15:1447-58.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Landewe RB, Boers M, )17.7 (V)110.8 (erhoeven )54.8 (AC, et al. COBRA)-220.2 (combination)]TJ
2.175 -1.25 Td
(therapy in patients with early rheumatoid arthritis: Long-term )Tj
T*
[(structural benefits of a brief intervention. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:347-56.)Tj
-0.00011 Tc 0.02499 Tw 30.825 26.25 Td
[(23.)-875.1 (Cooper NJ. Economic burden of rheumatoid arthritis: a systematic)]TJ
2.175 -1.25 Td
[(review)64.8 (. Rheumatology Oxford 2000;39:28-33.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Ferraz MB, Maetzel )54.8 (A, Bombardier C. )54.8 (A)-220.1 (summary of economic)]TJ
2.175 -1.25 Td
(evaluations published in the field of rheumatology and related)Tj
T*
[(disciplines. )54.8 (Arthritis Rheum 1997;40:1587-93.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Lambert CM, Hurst NP)110.8 (, Forbes JF)79.7 (, Lochhead )54.8 (A, Macleod M, Nuki)]TJ
2.175 -1.25 Td
(G. Is day care equivalent to inpatient care for active rheumatoid)Tj
T*
(arthritis? Randomised controlled clinical and economic evaluation.)Tj
0 Tc T*
(BMJ 1998;316:965-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Magnusson S. )17.7 (T)35 (reatment of rheumatoid arthritis \321 does it af)17.7 (fect)]TJ
2.175 -1.25 Td
[(society\325)54.8 (s cost for the disease? Br J Rheumatol 1996;35:791-5.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (McIntosh E. )17.7 (The cost of rheumatoid arthritis. Br J Rheumatol)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1996;35:781-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Y)99.8 (elin E. )17.7 (The cost of rheumatoid arthritis: absolute, incremental, and)]TJ
2.175 -1.25 Td
[(mar)17.7 (ginal estimates. J Rheumatol 1996;23:47-51.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Posnett J, Jan S. Indirect cost in economic evaluation: the )]TJ
2.175 -1.25 Td
(opportunity cost of unpaid inputs. Health Econ 1996;5:13-23.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Merkesdal S, Ruof J, Sch\232f)17.7 (fski O, Bernitt K, Zeidler H, Mau )17.7 (W)91.9 (.)]TJ
2.175 -1.25 Td
(Indirect medical costs in early rheumatoid arthritis: composition of)Tj
T*
(and changes in indirect costs within the first three years of disease.)Tj
T*
(Arthritis Rheum 2001;44:528-34.)Tj
ET
0 0 0 1 K
43 72 m
547 72 l
S
BT
/T1_2 1 Tf
8 0 0 8 413.3613 53.9844 Tm
(The Journal of Rheumatology 2004; 31:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1716)Tj
ET
0 0 0 0 k
/GS0 gs
95.25 76.75 396.47 -10.83 re
f*
0.5 w
95.25 76.75 396.47 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\4$P%bb%.!jF\EbQK:\T*)MuniMKg9m(lai.FE%g_Y/Iu7"Q\R/rn_FX\h^o=F
Q^,[,e?%%'L(lMuCehR:0h9R*K2dkeglZ5jG9Bcfl_2GVH30jtc.-%TjJl*?=7Zbk
HDSpB'-SSkKR&k4:nI>JiYAUp#eY/b`Xc6(4GoR@/r'@N67X@QlahRd,-([iRj`=!
i^AN=9cAuI7_u\CQZBjaU*:>4g><@$0$5cC@oOtt_L*?ibE^BkAYlBj/T[`!ZuV,n
;!r#1DB`-\HR4P$Jp\)\2)ueuD3%TXj]45G'JM#W?#_:N=#_$Ug,@GnkQOT-g*G@0
_Zn8?5uk`[p#sZ/cC,X',ikNbqjb&6g7Bup)umeK^Lc1'5nF/b&-P91"@3S#p_#g]
39Ts;)ZH)d]jAQ?i@t>93m`N~>
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
100 0 obj
<>
endobj
66 0 obj
<>
endobj
62 0 obj
<>
endobj
83 0 obj
<>
endobj
122 0 obj
<>
endobj
63 0 obj
<>
endobj
75 0 obj
<>stream
HV{PSwKE1 pڎm-OD@"H!
HH R^BxA)-*e]u.3.ggo3p qA~q|^ Ck1v8ր'5&M!C
Gq~5b7*,
MfV'c,'+Z:9; "At<z]7}q7} JJ~>)%E< ?ʉbZEُ1ͣ%"^?':K}B4OyQ["Z'EQHڏa12>ac_6þü{Ax ބ62(0xAD톘Pf
Q-Hq_VWV[DiU9'8ML}L0dssyhIj5beh5f,kSF6<۽ܕviiav'X=/yȻQSƾg8dD"~J{`g˪pMJNBj:yӭd{ ++mUaᜧcU\%Īt$uL5v]֡\t}KkkʛFyXno):xJ.Y_#-מ4!mȗ$G{ Dm6s[U!|
<4`